K-252a is a protein kinase inhibitor targeting serine-threonine, tyrosine, and CAM kinases. In vitro, it blocks NGF-induced TrkA signalling and neural differentiation, exhibiting antitumour, antibacterial, anti-inflammatory, and neuroprotective activities.

PKA:140 nM, PKC:470 nM, Phosphorylase kinase:1.7 nM, Ca2+/calmodulin-dependent kinase type II:270 nM

Methods: LINC00641 overexpressing cell lines were treated with K-252a (1.7 nM, 6 hours), and the expression of target proteins in cells was detected by Western blotting.
Results: K-252a can reduce the levels of p-Akt and p-TrkB in LINC00641 overexpressing cell lines. [3]
Methods: PC12 subclone h cells were treated with K-252a (3-100 nM, 8 days) to study its effect on cell viability.
Results: K-252a can inhibit NGF-induced neurite outgrowth. [4]

Methods: Mice were treated with K-252a (20 mg/kg, intraperitoneal injection, once a day for 5 days) and their neurological function was evaluated. Results: K-252a was able to inhibit the TH-induced neuroprotective effect in mice. [5]